Program in Clinical and Experimental Therapeutics, College of Pharmacy, University of Georgia, Augusta,GA 30912-2450, USA.
Pharmacotherapy. 2010 Feb;30(2):169-76. doi: 10.1592/phco.30.2.169.
Angiogenesis is an important process for a variety of physiologic and pathologic conditions. Different angiogenic modulating targets are under extensive investigation both experimentally and clinically. The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are the first-line agents used in hypercholesterolemia. They are also characterized by having other benefits apart from their lipid-lowering effects. Among these pleiotropic effects are the pro- and antiangiogenic properties of statins. The pleiotropic effects of statins and how they modulate new blood vessel formation are discussed in this review. The currently available data from both animal and human studies regarding the effects of statins on angiogenesis in ischemic heart disease, stroke, ocular diseases, and cancer are also reviewed. Statins are safe, orally available agents that may acquire novel therapeutic indications through their angiogenic modulating effects.
血管生成是多种生理和病理状况的重要过程。不同的血管生成调节靶点正在进行广泛的实验和临床研究。3-羟基-3-甲基戊二酰辅酶 A 还原酶抑制剂（他汀类药物）是治疗高胆固醇血症的一线药物。它们除了具有降低血脂的作用外，还具有其他益处。这些多效性作用包括他汀类药物的促血管生成和抗血管生成特性。本文综述了他汀类药物的多效性作用及其对新血管形成的调节作用。还综述了目前关于他汀类药物对缺血性心脏病、中风、眼部疾病和癌症中血管生成影响的动物和人体研究的现有数据。他汀类药物是安全的、口服的药物，通过其血管生成调节作用可能获得新的治疗适应证。
